GSK-LSD1, a KDM1A inhibitor, has demonstrated significant efficacy in inhibiting thyroid cancer progression and increasing chemotherapy sensitivity, suggesting potential clinical applications for advanced thyroid cancers (79). The gene discussed is KDM1A; the disease is thyroid gland carcinoma.